FDA to accelerate review of Wyeth infant vaccine

05/8/2009 | Forbes

The FDA granted priority-review status to Wyeth's infant vaccine Prevnar 13. The drug protects against seven strains of Streptococcus pneumoniae bacteria already included in the original Prevnar formulation, plus six other strains that cause similar infectious diseases.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX